P495 Usefulness of a capsule endoscopy scoring system in understanding the disease state of Crohn’s disease
ECCO'20 Vienna
2020
P496 Feasibility and safety of single incision laparoscopic surgery for patients with complex Crohn’s disease
ECCO'20 Vienna
2020
P498 Loss of response of anti-TNF in Crohn’s disease patients single-centre experience
ECCO'20 Vienna
2020
P499 Objectively assessed disease activity during ustekinumab treatment in a nationwide real-life Crohn’s disease cohort
ECCO'20 Vienna
2020
P503 Changes in clinical use of vedolizumab are driven by lower drug costs and are associated with better outcomes: a real-life single-centre Spanish experience
ECCO'20 Vienna
2020
P504 Remote cannabis-therapy management platform for IBD patients: performance assessment
ECCO'20 Vienna
2020
P506 Increased risk of anti-drug antibodies to a second anti-TNF in patients who developed antibodies to the first anti-TNF
ECCO'20 Vienna
2020
P509 Vedolizumab levels in breast milk: Results from a prospective, postmarketing, milk-only lactation study in nursing mothers with inflammatory bowel disease
ECCO'20 Vienna
2020
P510 Dose escalation of subcutaneous vedolizumab in patients with ulcerative colitis: A post hoc analysis of the VISIBLE trial data
ECCO'20 Vienna
2020
P511 Association of ustekinumab serum concentrations and clinical outcomes: results from the mUST-DECIDE trial
ECCO'20 Vienna
2020